FINWIRES · TerminalLIVE
FINWIRES

Zscaler Reported 'Decent' Fiscal Q3 but Offered Mixed Guidance, RBC Says

By

Zscaler (ZS) delivered a "decent" fiscal Q3, outperforming across most key metrics, though fiscal 2026 guidance was mixed, RBC Capital Markets said Tuesday in a note.

Fiscal 2026 annual recurring revenue guidance was raised by $7 million, less than the $19 million beat on consensus, which is just a pass-through of the Red Canary beat, the brokerage said.

Free cash flow margin guidance was lowered as a result of pull-forward on investments expected in fiscal 2027 to Q4, in order to lock in equipment prices ahead of potential increases, resulting in high single-digit capital expenditure versus expectations of mid-single-digit expenditure, according to the note.

Zscaler offered preliminary fiscal 2027 guidance of total ARR and revenue growth of 16% to 17% versus consensus of 18.4% and 19.5%, respectively, the brokerage added.

The company expects fiscal 2027 capital expenditure to be 200 basis points higher, and will exclude Red Canary renewals from its net new annual recurring revenue calculations, which had a positive impact in fiscal 2026. It will stop reporting Red Canary in fiscal 2027, the note said.

RBC kept an outperform rating on Zscaler with a price target of $205.

Shares of Zscaler were down more than 31% in Wednesday trading.

Price: $126.84, Change: $-57.76, Percent Change: -31.29%

Related Articles

Wire

Ooma Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Ooma (OOMA) reported fiscal Q1 adjusted earnings late Tuesday of $0.35 per diluted share, up from $0.20 a year earlier.Analysts polled by FactSet expected $0.32.Revenue in the three months ended April 30 rose to $81.1 million from $65 million a year earlier.Analysts surveyed by FactSet expected $79.8 million.Ooma expects fiscal Q2 adjusted EPS of $0.33 to $0.34 on revenue of $81.6 million to $82.3 million.Analysts polled by FactSet expect EPS of $0.31 on revenue of $80.2 million.The company boosted fiscal 2027 adjusted EPS guidance to $1.29 to $1.34 on revenue of $326 million to $328.5 million. Prior guidance was EPS of $1.26 to $1.31 on revenue of $321 million to $325 million.Analysts surveyed by FactSet expect EPS of $1.29 on revenue of $322.8 million.Ooma shares rose 4.8% in after-hours trading.

$OOMA
Wire

Jade Biosciences Says First Participant Dosed in First-in-Human Phase 1 Trial of JADE201

Jade Biosciences (JBIO) said late Tuesday the first participant has been dosed in a first-in-human phase 1 clinical trial of JADE201, an investigational, half-life extended, afucosylated monoclonal antibody.The first-in-human trial is a placebo-controlled study assessing single ascending doses of JADE201 in participants with rheumatoid arthritis, according to a statement.Jade said interim phase 1 data in rheumatoid arthritis anticipated in 2027 are expected to inform indication prioritization across potential autoimmune indications supported by B cell activating factor receptor biology.

$JBIO
Wire

Zscaler Fiscal Q3 Adjusted Earnings, Revenue Rise; Q4 Guidance Set

Zscaler (ZS) reported fiscal Q3 adjusted earnings late Tuesday of $1.08 per diluted share, up from $0.84 a year earlier.Analysts polled by FactSet expected $1.01.Revenue for the three months ended April 30 was $850.5 million, up from $678 million a year earlier.Analysts surveyed by FactSet expected $835.6 million.For fiscal Q4, the company expects adjusted EPS of $1.08 to $1.09 on revenue of $875 million to $878 million. Analysts expect EPS of $1.03 on revenue of $878.6 million.For the full-year fiscal 2026, the company now expects adjusted EPS of $4.10 to $4.11 on revenue of $3.329 billion to $3.332 billion. It earlier expected adjusted EPS of $3.99 to $4.02 on revenue of $3.31 billion to $3.32 billion.Analysts expect EPS of $4.01 on revenue of $3.32 billion.

$ZS